Cargando…
Connecting GWAS Susceptibility Genes in COPD: Do We Need to Consider TGF-β2?
Autores principales: | Chen, Qing, Heijink, Irene H., de Vries, Maaike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641857/ https://www.ncbi.nlm.nih.gov/pubmed/34411507 http://dx.doi.org/10.1165/rcmb.2021-0265ED |
Ejemplares similares
-
Biosimilar therapeutics—what do we need to consider?
por: Schellekens, Huub
Publicado: (2009) -
Women and COPD: do we need more evidence?
por: Gut-Gobert, Christophe, et al.
Publicado: (2019) -
Precision medicine in COPD: where are we and where do we need to go?
por: Sidhaye, Venkataramana K., et al.
Publicado: (2018) -
Finding the ‘missing millions’: do we need incentives to optimise COPD outcomes?
por: Roberts, June, et al.
Publicado: (2013) -
Increasing Smoking Cessation Adherence: Do We Need to Consider the Role of Executive Function and Rumination?
por: Masiero, Marianna, et al.
Publicado: (2020)